Industry News
Pharmaceutical Industry News
Genentech and Novartis have…
Genentech and Novartis have sponsored a four-part microdrama series about young people with food allergies in New York.
Novo Nordisk CEO Mike Doustdar…
Novo Nordisk CEO Mike Doustdar told Fierce in an interview that he always believed the Big Pharma “did actually need to become more competitive.”
May saw a drug ad spending slump…
May saw a drug ad spending slump across the majority of the top ten drug ad spenders with AbbVie's Skyrizi and RInvoq, Johnson & Johnson's Tremfya and more all decreasing their monthly TV ad spend.
Inclusion on the Pentagon’s…
Inclusion on the Pentagon’s 1260H list automatically makes WuXi AppTec one of the “biotechnology companies of concern” under the Biosecure Act. WuXi AppTec maintains that its place on the list was "clearly a mistake," a
A combination of Merck’s…
A combination of Merck’s islatravir and Gilead’s lenacapavir has succeeded in two phase 3 trials and is in line to become the first long-acting oral HIV treatment that can be taken weekly.
Merck & Co. and Gilead are…
Merck & Co. and Gilead are pulling the plug on the phase 3 Evoke-03 trial evaluating Trodelvy, combined with Keytruda, as a first-line treatment in patients with PD-L1-high non-small cell lung cancer.
Almost two-thirds of Americans who…
Almost two-thirds of Americans who have asked artificial intelligence tools for medical advice acted on the guidance without consulting a doctor, an eHealth survey of more than 1,000 people found.
Medical Advances Are Keeping a Health Reporter Busy
A conversation with Gina Kolata, who covers breakthroughs in medical science.
The LinkedIn activities of…
The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing watchdog identifying eight breaches of its rules in the latest of a series of cases.
With an obesity green light…
With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes.
Eli Lilly emerged as the “clear…
Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”
Actress Mariska Hargitay looks…
Actress Mariska Hargitay looks back on her late father's multiple myeloma journey in BMS' "Investigate Myeloma" campaign, highlighting its emerging CELMoD research.
For Novo Nordisk, the launch of…
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the chronic weight management market
The FDA has expanded the label for…
The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor
Hikma Pharmaceuticals plans to…
Hikma Pharmaceuticals plans to spend $267 million to expand a pair of manufacturing facilities in Ohio as part of the $1 billion the U.K. drugmaker committed a year ago to build out its U.S. operations.
As Amgen strives to become the top…
As Amgen strives to become the top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions in New Orleans this past
The company adjusted its full-year…
The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).
The FDA is going forward with…
The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiative that could allow the Trump administration to impose restrictions on its use, The Wall Street Journal reports.
Each year, the global oncology…
Each year, the global oncology community descends on Chicago for ASCO, where buzzy data drops, practice-changing posters and packed sessions offer a look at where cancer care is headed next. In this week’s episode of
With a resounding unanimous vote,…
With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.